[go: up one dir, main page]

SG10202006685XA - Treatment of Cancers Using Anti-NKG2A Agents - Google Patents

Treatment of Cancers Using Anti-NKG2A Agents

Info

Publication number
SG10202006685XA
SG10202006685XA SG10202006685XA SG10202006685XA SG10202006685XA SG 10202006685X A SG10202006685X A SG 10202006685XA SG 10202006685X A SG10202006685X A SG 10202006685XA SG 10202006685X A SG10202006685X A SG 10202006685XA SG 10202006685X A SG10202006685X A SG 10202006685XA
Authority
SG
Singapore
Prior art keywords
cancers
treatment
nkg2a
agents
nkg2a agents
Prior art date
Application number
SG10202006685XA
Inventor
Pascale Andre
Mathieu Blery
Caroline Soulas
Nicolaï Wagtmann
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of SG10202006685XA publication Critical patent/SG10202006685XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10202006685XA 2014-10-23 2015-10-23 Treatment of Cancers Using Anti-NKG2A Agents SG10202006685XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462067642P 2014-10-23 2014-10-23

Publications (1)

Publication Number Publication Date
SG10202006685XA true SG10202006685XA (en) 2020-08-28

Family

ID=54347541

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202006685XA SG10202006685XA (en) 2014-10-23 2015-10-23 Treatment of Cancers Using Anti-NKG2A Agents
SG11201701388UA SG11201701388UA (en) 2014-10-23 2015-10-23 Treatment of cancers using anti-nkg2a agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201701388UA SG11201701388UA (en) 2014-10-23 2015-10-23 Treatment of cancers using anti-nkg2a agents

Country Status (10)

Country Link
US (2) US10329348B2 (en)
EP (2) EP3659625A1 (en)
JP (1) JP6889660B2 (en)
KR (1) KR102598068B1 (en)
CN (1) CN107073116A (en)
AU (1) AU2015334886B9 (en)
IL (1) IL250677B (en)
RU (1) RU2721271C2 (en)
SG (2) SG10202006685XA (en)
WO (1) WO2016062851A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3409289T1 (en) 2010-02-26 2020-12-31 Novo Nordisk A/S Stable antibody containing compositions
CN103635487B (en) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 Selective elimination of erosive cells
CA2959463A1 (en) 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
KR102748822B1 (en) 2014-09-16 2025-01-03 이나뜨 파르마 에스.에이. Neutralization of inhibitory pathways in lymphocytes
SG10202006685XA (en) 2014-10-23 2020-08-28 Innate Pharma Treatment of Cancers Using Anti-NKG2A Agents
WO2017016805A1 (en) 2015-07-24 2017-02-02 Innate Pharma Methods for detecting tissue infiltrating nk cells
LT3405495T (en) 2016-01-21 2021-08-10 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
DE102017001875A1 (en) * 2017-02-27 2018-08-30 Wolfgang Würfel Drug for malignant treatment
DE102017005815A1 (en) * 2017-06-20 2018-12-20 Wolfgang Würfel Vaccine for the treatment of a malignancy
AU2018298673A1 (en) * 2017-07-10 2019-12-19 Innate Pharma Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
EP3755371A4 (en) * 2018-02-23 2021-11-24 Abexxa Biologics, Inc. Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen
US11464840B2 (en) 2018-02-26 2022-10-11 Swey-Shen Chen Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers
JP7455749B2 (en) * 2018-03-13 2024-03-26 インネート ファーマ Treatment of head and neck cancer
EP3793607A1 (en) 2018-05-15 2021-03-24 MedImmune Limited Treatment of cancer
US20210253713A1 (en) * 2018-07-23 2021-08-19 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use
US12534526B2 (en) * 2018-11-07 2026-01-27 Shanghai Hyamab Biotech Co., Ltd. NKG2A antibody, preparation method therefor and application thereof
JP7520003B2 (en) 2018-11-16 2024-07-22 ブリストル－マイヤーズ スクイブ カンパニー Anti-NKG2A Antibodies and Uses Thereof
WO2020259707A1 (en) * 2019-06-28 2020-12-30 科济生物医药（上海）有限公司 Cell for resisting transplant reaction and method
CN114901689A (en) * 2019-10-14 2022-08-12 先天制药公司 Treatment of cancer with ILT-2 inhibitors
US10981996B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981997B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
AU2022286617A1 (en) 2021-06-01 2023-12-21 Les Laboratoires Servier Anti-nkg2a antibodies and compositions
EP4644422A1 (en) * 2022-12-28 2025-11-05 BioRay Pharmaceutical Co., Ltd. Anti-nkg2a antibody and use thereof
CN119033938A (en) * 2023-01-21 2024-11-29 四川大学华西医院 Application of RGS18 in treatment of tumor metastasis

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US122637A (en) 1872-01-09 Improvement in vapor-burners
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5459061A (en) 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE188874T1 (en) 1992-08-18 2000-02-15 Centro Inmunologia Molecular MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR, CELLS AND METHODS FOR THE PRODUCTION THEREOF AND COMPOSITIONS CONTAINING THEM
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
IT1277827B1 (en) 1995-03-01 1997-11-12 Ministero Uni Ricerca Scient E CHIMERIC MURINE/HUMAN MONOCLONAL ANTIBODY OR ITS FRAGMENT SPECIFIC FOR THE EGF RECEPTOR (EGF-R)
JPH11507535A (en) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド Antibodies and antibody fragments that suppress tumor growth
US5942602A (en) 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
ES2601882T5 (en) 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedure to monitor the activity of an immunofunctional molecule
US6794494B1 (en) 2003-04-14 2004-09-21 Arius Research, Inc. Cancerous disease modifying antibodies
JP2003533987A (en) 2000-05-19 2003-11-18 イス ケミカル カンパニー リミテッド Humanized antibodies against epidermal growth factor receptor
JP2004519233A (en) 2001-02-19 2004-07-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Modified anti-EGFR antibodies with reduced immunogenicity
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
PT1392359E (en) 2001-05-11 2010-01-27 Ludwig Inst For Cancer Res Ltd Specific binding proteins and uses thereof
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CN100497389C (en) 2001-06-13 2009-06-10 根马布股份公司 Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AU2002326531A1 (en) 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
EP1421113A4 (en) 2001-08-03 2005-04-13 Commw Scient Ind Res Org SCREENING METHODS BASED ON CRYSTALLINE EGF RECEPTOR STRUCTURE
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DE60334453D1 (en) 2002-05-30 2010-11-18 Macrogenics Inc CD16A BINDING PROTEINS AND USE FOR THE TREATMENT OF IMMUNE DISEASES
ES2381617T5 (en) 2002-08-14 2016-02-24 Macrogenics, Inc. Specific antibodies against FcgammaRIIB and its procedures for use
JP2004126818A (en) 2002-09-30 2004-04-22 Toshiba Corp Electronic device system, battery unit, and operation control method for battery unit
AU2003304145A1 (en) 2002-10-18 2004-12-13 Macrogenics, Inc. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP3803790B2 (en) 2003-02-17 2006-08-02 株式会社東北テクノアーチ Novel diabody-type bispecific antibody
BRPI0411803A (en) 2003-06-27 2006-05-23 Abgenix Inc antibodies directed to epidermal growth factor receptor deletion mutants and their uses
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
EP1701979A2 (en) 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
MXPA06011796A (en) 2004-04-16 2007-05-07 Macrogenics Inc FCgammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF.
MXPA06012601A (en) 2004-05-10 2007-05-10 Macrogenics Inc HUMANIZED FcgammaRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF.
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
DK1831258T4 (en) * 2004-12-28 2023-08-28 Innate Pharma Sa Monoklonale antistoffer mod NKG2A
RU2488597C2 (en) 2005-02-07 2013-07-27 Гликарт Биотехнологи Аг Antigen-binding molecules, which bind egfr, their coding vectors and their usage
MX2007015107A (en) 2005-06-03 2008-02-15 Genentech Inc Method of producing antibodies with modified fucosylation level.
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
SG170110A1 (en) 2006-03-10 2011-04-29 Macrogenics Inc Identification and engineering of antibodies with variant heavy chains and methods of using same
EP2021029B1 (en) 2006-05-26 2014-06-11 MacroGenics, Inc. Humanized fc gamma riib-specific antibodies and methods of use thereof
US7932055B2 (en) 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
BRPI0712953B8 (en) 2006-06-30 2021-05-25 Novo Nordisk As anti-nkg2a antibodies, their use, and pharmaceutical composition
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE
JP5774312B2 (en) 2008-01-24 2015-09-09 ノボ・ノルデイスク・エー／エス Humanized anti-human NKG2A monoclonal antibody
SG174963A1 (en) 2009-03-31 2011-11-28 Roche Glycart Ag Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
SI3409289T1 (en) 2010-02-26 2020-12-31 Novo Nordisk A/S Stable antibody containing compositions
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
CN103635487B (en) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 Selective elimination of erosive cells
EP3186282A1 (en) 2014-08-28 2017-07-05 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
CA2959463A1 (en) 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
KR102748822B1 (en) 2014-09-16 2025-01-03 이나뜨 파르마 에스.에이. Neutralization of inhibitory pathways in lymphocytes
SG10202006685XA (en) 2014-10-23 2020-08-28 Innate Pharma Treatment of Cancers Using Anti-NKG2A Agents
LT3405495T (en) 2016-01-21 2021-08-10 Innate Pharma Neutralization of inhibitory pathways in lymphocytes

Also Published As

Publication number Publication date
WO2016062851A1 (en) 2016-04-28
RU2721271C2 (en) 2020-05-18
US11225519B2 (en) 2022-01-18
RU2017107559A3 (en) 2019-04-15
JP2017537069A (en) 2017-12-14
EP3659625A1 (en) 2020-06-03
KR102598068B1 (en) 2023-11-06
US20190322744A1 (en) 2019-10-24
JP6889660B2 (en) 2021-06-18
AU2015334886B2 (en) 2021-06-10
KR20170070076A (en) 2017-06-21
US20170313773A1 (en) 2017-11-02
CA2959841A1 (en) 2016-04-28
SG11201701388UA (en) 2017-03-30
AU2015334886B9 (en) 2021-07-08
CN107073116A (en) 2017-08-18
IL250677B (en) 2021-03-25
IL250677A0 (en) 2017-03-30
RU2017107559A (en) 2018-11-27
AU2015334886A1 (en) 2017-03-16
US10329348B2 (en) 2019-06-25
EP3209687A1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
IL250677A0 (en) Treatment of cancers using anti-nkg2a agents
IL259783A (en) Methods of treatment of malignancies
PL3851537T3 (en) Treatment of hyperbilirubinemia
GB201701673D0 (en) Methods of well treatment
PL3122358T3 (en) Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
IL247267A0 (en) Improved methods for the treatment of vascularizing cancers
IL247859A0 (en) Cancer treatment
IL263835A (en) Exosome-guided treatment of cancer
IL246880A0 (en) Treatment of neoplasia
GB201416832D0 (en) Methods of treatment
GB201408297D0 (en) Treatment of cancer
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201407837D0 (en) Methods of cancer therapy
GB201411027D0 (en) Treatment
GB201417456D0 (en) Treatment of cancer
GB201512139D0 (en) Methods of treatment
GB201412411D0 (en) Treatment
GB201417465D0 (en) Treatment of cancers
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer
PT3851537T (en) Treatment of hyperbilirubinemia
GB201622214D0 (en) treatment of cancer
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer